We investigated serum (IL-10 and IL-12p70) and cellular cytokine levels (IL-10, IL-12p40, IL-12p70, IFN-γ) in stimulated PBMC over 24 weeks in 15 relapsing-remitting multiple sclerosis (MS) patients randomized to receive once-weekly (qw) IFN-β-1a 30 μg intramuscularly (IM) (n = 8) or three-times-weekly (tiw) IFN-β-1a 44 μg subcutaneously (SC) (n = 7). Overall, IFN-β treatment increased cellular IL-10 (p b 0.01) levels and the ratios of cellular IL-10/IL-12p40 (p b 0.01) and IL-10/IL-12p70 (p b 0.02) while cellular IFN-γ levels were reduced (p b 0.01). Serum IL-10 levels were decreased in non-responders to therapy based on MRI-defined criteria (p b 0.01) but did not change in responders over the course of treatment. In addition, non-responders demonstrated a decrease in serum IL-10/IL-12p70 ratio (p = 0.031) and a decrease in cellular IL-12p70 (p b 0.02). A decrease in cellular IFN-γ was observed in responders (p = 0.013). This is the first study that compares cytokine changes between the two IFN-β regimes and demonstrates that serum IL-10 levels decrease in those patients who continue to have active MRI lesions while on interferon-beta therapy.
Introduction
Multiple cytokines and immune cell subsets have been implicated in disease activity in MS. Current research suggests that no one cytokine or cell subset is wholly responsible for disease induction, relapse severity or remission, but instead that a complex interplay of factors controls disease activity. Heterodimeric IL-12 is mainly secreted by monocytes and dendritic cells as two proteins, IL-12p40 and IL-12p35 which combine to form biologically active IL-12p70. An alternate heterodimer, IL-23p19, binds to IL-12p40 to produce IL-23, which has been implicated in disease activity in murine models of MS. IL-12 acts as an inflammatory cytokine inducer through activation and maturation of Th1 cells secreting IFN-γ. IL12p40 levels are increased in MS peripheral blood mononuclear cells (PBMC) and acute CNS plaques, while IL-12p35 levels are decreased (Windhagen et al., 1995; Van Boxel-Dezaire et al., 1999) . IL-12 levels correlate with clinical measures of disease activity (EDSS) and presence of MRI lesions (Makhlouf et al., 2001) . IL-10 is produced by dendritic cells, macrophages, B cells and T cells (especially of the Th2 type). IL-10 acts to decrease inflammatory cytokine production by macrophages (Imitola et al., 2005) . IL-10 secretion by PBMC from MS patients is decreased prior to relapse and increased during remission (Rieckmann et al., 1994; Pelfrey et al., 2000; Waubant et al., 2001) . Endogenous IL-10 levels may also influence severity of disease (Luomala et al., 2003; Van BoxelDezaire et al., 1999) . IFN-γ is a cytokine product of NK and T
